BMEA

Biomea Fusion Inc · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website biomeafusion.com
Employees(FY) 103
ISIN US09077A1060

Performance

-27.07%

-34.11%

-51.44%

-12.78%

-70.87%

YTD

-69.24%

Profile

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Advanced Technical Analysis

Technical Analysis of BMEA 2024-12-20

The Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 60 suggests a bullish outlook, and the overall Technical Score of 35 reinforces a bearish trend. This mixed signal implies that despite some bullish momentum from oscillators, the prevailing sentiment remains bearish, warranting caution for potent...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BMEA

Stock Rank

Recent News & Updates

2024-12-16 21:41
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?(Yahoo Finance)
2024-12-16 19:10
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes(Globenewswire)
2024-12-16 05:15
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)(Globenewswire)
2024-12-12 04:02
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)(Globenewswire)
2024-12-12 04:02
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)(Yahoo Finance)
2024-12-09 03:01
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia(Yahoo Finance)
2024-12-05 19:00
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia(Globenewswire)
2024-12-02 03:05
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-11-17 19:00
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)(Globenewswire)
2024-11-01 04:05
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-10-30 04:00
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate(Globenewswire)
2024-10-29 04:46
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights(Globenewswire)
2024-10-20 21:00
Biomea Fusion Announces Approval of icovamenib as International Nonproprietary Name for BMF-219(Globenewswire)
2024-10-15 04:05
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 R(Globenewswire)
2024-10-09 20:57
Morning Movers: Arcadium Lithium surges after deal to be acquired(Yahoo Finance)
2024-10-06 21:00
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)(Globenewswire)
2024-09-30 21:00
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts(Globenewswire)
2024-09-27 00:20
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate(Yahoo Finance)
2024-09-26 23:13
Biomeas stock bounces back as FDA lifts clinical hold on diabetes trials(Yahoo Finance)
2024-09-26 02:00
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials(Globenewswire)
2024-08-13 21:55
Wall Street Analysts Think Biomea Fusion (BMEA) Could Surge 317.86%: Read This Before Placing a Bet(Yahoo Finance)
2024-08-01 04:05
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-07-31 10:54
BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024(Investorplace)
2024-07-31 04:05
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights(Globenewswire)
2024-06-29 08:32
Biomea Fusion, Inc. (BMEA): Why Did Analysts Give This Biotech Penny Stock a Moderate Buy Rating?(Insidermonkey)
2024-06-29 06:30
10 Best Biotech Penny Stocks to Buy Now(Insidermonkey)
2024-06-27 14:21
Why Are Hedge Funds Shorting Biomea Fusion, Inc. (BMEA)?(Insidermonkey)
2024-06-26 11:08
What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting(Insidermonkey)
2024-06-16 21:00
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies(Globenewswire)
2024-06-10 23:34
Biomea Fusion, Inc. (NASDAQ:BMEA) Downgraded by Barclays(Yahoo Finance)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.